Vaxart Inc (VXRT)
0.70
-0.01
(-2.06%)
USD |
NASDAQ |
May 01, 16:00
0.70
0.00 (0.00%)
After-Hours: 19:02
Vaxart Research and Development Expense (Quarterly): 14.70M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 14.70M |
| September 30, 2023 | 15.00M |
| June 30, 2023 | 18.81M |
| March 31, 2023 | 19.62M |
| December 31, 2022 | 20.46M |
| September 30, 2022 | 22.47M |
| June 30, 2022 | 19.93M |
| March 31, 2022 | 18.20M |
| December 31, 2021 | 15.53M |
| September 30, 2021 | 12.41M |
| June 30, 2021 | 10.74M |
| March 31, 2021 | 10.07M |
| December 31, 2020 | 8.591M |
| September 30, 2020 | 4.616M |
| June 30, 2020 | 5.114M |
| March 31, 2020 | 1.542M |
| December 31, 2019 | 3.291M |
| September 30, 2019 | 3.713M |
| June 30, 2019 | 3.707M |
| March 31, 2019 | 3.829M |
| December 31, 2018 | 4.474M |
| September 30, 2018 | 4.381M |
| June 30, 2018 | 5.012M |
| March 31, 2018 | 3.408M |
| December 31, 2017 | 2.50M |
| Date | Value |
|---|---|
| September 30, 2017 | 2.80M |
| June 30, 2017 | 3.70M |
| March 31, 2017 | 6.80M |
| December 31, 2016 | 10.20M |
| September 30, 2016 | 7.60M |
| June 30, 2016 | 5.90M |
| March 31, 2016 | 8.50M |
| December 31, 2015 | 6.30M |
| September 30, 2015 | 5.50M |
| June 30, 2015 | 5.30M |
| March 31, 2015 | 4.80M |
| December 31, 2014 | 4.80M |
| September 30, 2014 | 4.90M |
| June 30, 2014 | 6.20M |
| March 31, 2014 | 4.10M |
| December 31, 2013 | 4.20M |
| September 30, 2013 | 3.00M |
| June 30, 2013 | 6.345M |
| March 31, 2013 | 4.936M |
| December 31, 2012 | -0.382M |
| September 30, 2012 | 3.145M |
| June 30, 2012 | 1.33M |
| March 31, 2012 | 1.518M |
| December 31, 2011 | 1.586M |
| September 30, 2011 | 4.388M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.542M
Minimum
Mar 2020
22.47M
Maximum
Sep 2022
12.03M
Average
12.41M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Novavax Inc | 164.70M |
| aTyr Pharma Inc | 12.76M |
| Allogene Therapeutics Inc | 54.66M |
| AIM ImmunoTech Inc | 3.20M |
| Protalix BioTherapeutics Inc | 3.102M |